Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1304 views | HTML 3017 views | ?
Andric C. Perez-Ortiz1,2, Israel Ramírez1, Juan C. Cruz-López3,*, Cynthia Villarreal-Garza4,*, Alexandra Luna-Angulo5, Esmeralda Lira-Romero1, Salvador Jiménez-Chaidez1, José Díaz-Chávez6, Juan A. Matus-Santos6, Laura Sánchez-Chapul5, Patricia Mendoza-Lorenzo7 and Francisco J. Estrada-Mena1
1Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico
2Yale University School of Public Health, Laboratory of Epidemiology and Public Health, New Haven, CT, USA
3Hospital Regional ISSSTE Puebla and Hospital General Zona Norte SSEP Puebla, Puebla City, Mexico
4Depto. de Investigacion, Instituto Nacional de Cancerologia, Centro de Cancer de Mama, Tecnologico de Monterrey, Monterrey, Nuevo León, Mexico
5Instituto Nacional de Rehabilitación, Mexico City, Mexico
6Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerología, Mexico City, Mexico
7División Académica de Ciencias Básicas, Unidad Chontalpa, Universidad Juárez Autónoma de Tabasco, Tabasco, Mexico
*These authors contributed equally to this work
Francisco J. Estrada-Mena, email: [email protected]
Keywords: pharmacogenetics; paclitaxel; breast cancer; genetic markers; single nucleotide polymorphism
Received: July 27, 2017 Accepted: October 27, 2017 Published: November 15, 2017
Locally advanced breast cancer (LABC) cases have a varying five-year survival rate, mainly influenced by the tumor response to chemotherapy. Paclitaxel activity (response rate) varies across populations from 21.5% to 84%. There are some reports on genetic traits and paclitaxel; however, there is still considerable residual unexplained variability. In this study, we aimed to test the association between eleven novel markers and tumor response to paclitaxel and to explore if any of them influenced tumor protein expression. We studied a cohort of 140 women with LABC. At baseline, we collected a blood sample (for genotyping), fine needle aspirates (for Western blot), and tumor measurements by imaging. After follow-up, we ascertained the response to paclitaxel monotherapy by comparing the percent change in the pre-, post- tumor measurements after treatment. To allocate exposure, we genotyped eleven SNPs with TaqMan probes on RT-PCR and regressed them to tumor response using linear modeling. In addition, we compared protein expression, between breast tumors and healthy controls, of those genes whose genetic markers were significantly associated with tumor response. After adjusting for multiple clinical covariates, SNPs on the LPHN2, ROBO1, SNTG1, and GRIK1 genes were significant independent predictors of poor tumor response (tumor growth) despite paclitaxel treatment. Moreover, proteins encoded by those genes are significantly downregulated in breast tumor samples.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.